Clinical trial · Interventional
Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma
Novel Imaging Modalities For Plexiform Neurofibromas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study was closed early due to poor accrual.
Summary
Brief summary (as posted)
RATIONALE: New imaging procedures such as fludeoxyglucose F 18 positron emission tomography (FDG-PET) and magnetic resonance (MR) perfusion imaging may improve the ability to detect disease progression, help doctors predict a patient's response to treatment, and help plan the most effective treatment. PURPOSE: This diagnostic trial is studying how well FDG-PET and MR perfusion imaging work in finding disease progression and determining response to treatment in patients with neurofibromatosis 1 and plexiform neurofibroma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neurofibromatosis Type 1 | — | UNRESOLVED | — |
| Precancerous Condition | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| fludeoxyglucose F 18 | Radiation | — | UNRESOLVED |
| gadopentetate dimeglumine | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 18FDG-PET scan and MR perfusion
- description
- Subjects will undergo MRI for quantitative (2D and 3D) evaluation of plexiform neurofibroma size, MR perfusion scan, and fludeoxyglucose (18FDG) PET scan at the time of study entry. Subjects who are treated for plexiform neurofibroma will undergo another 18FDG PET scan after one year of study entry.
- interventionNames
- Radiation: fludeoxyglucose F 18
- Radiation: gadopentetate dimeglumine
Primary outcomes (1)
- measure
- Tumor Progression as Measured by Tumor Area and Volume at 1 Year.
- timeFrame
- One year
- description
- We correlated SUVmax and change in tumor volume over the subsequent year
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 25 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Stratum 1:
* Diagnosis of neurofibromatosis 1 (NF1) and plexiform neurofibromas
* At high risk for progression, as defined by any of the following:
* Anatomic location such that progression carries a high risk of impairment of function, pain, or disfigurement (e.g., neck/mediastinum, paraspinal nerve roots, orbit, and face)
* Tumors that the patient, family, or caregiver believes have increased in size within the past year, but appear stable by standard clinical or radiographic measures
* No plexiform neurofibromas that are small, cause no pain or functional impairment, or are not likely to cause pain or functional impairment over the succeeding 12 months
* Stratum 2:
* Diagnosis of NF1 and progressive plexiform neurofibromas
* Neurofibroma progression documented by increase in lesion size on MRI
* Currently being enrolled on a clinical therapeutic trial at Children's Hospital of Philadelphia
PATIENT CHARACTERISTICS:
Age
* 25 and under
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
Other
* Not pregnant or nursing
* Negative pregnancy test
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* Stratum 1:
* No prior or concurrent chemotherapy
* No concurrent enrollment on a chemotherapy clinical trial
* Stratum 2:
* At least 4 weeks since prior chemotherapy
Endocrine therapy
* Not specified
Radiotherapy
* At least 6 weeks since prior radiotherapy (stratum 2)
Surgery
* Prior surgery for progressive plexiform neurofibroma allowed if incompletely resected and measurable disease remains (stratum 2)References
Publications (0)
Data not yet available